A pharmaceutical company brought on Christopher Gerardi to estimate economic damages arising from alleged infringement and at-risk launch of a patented oral antihyperglycemic drug used in the management of type 2 diabetes. The alleged economic damages were estimated according to appropriateness and, if so, quantum of lost profits, price erosion, and reasonable royalty elements.
IP Literature Watch: August 2022
Among the pieces featured in this month’s IP Literature Watch are a chapter exploring EU copyright framework relevant for the digitization of cultural...